Intravenous Immunoglobulin Market Scope, Growth, Size and Share by 2028
Intravenous Immunoglobulin Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 11.21 Billion |
| Market Size by 2028 | US$ 18.67 Billion |
| Global CAGR (2021 - 2028) | 7.6% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
Intravenous Immunoglobulin – Market Segmentation
The global intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and geography. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD). By Application, the market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others. By End User, the market is segmented into hospitals, specialty clinics, and others. By geography, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.
Company Profiles
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Pfizer Inc.
- ADMA Biologics Inc.
- Bio Products Laboratory Ltd.
- Shanghai RAAS
- Octapharma AG
- Kedrion S.p.A
- CSL Behring (CSL Limited)
- Prothya Biosolutions B.V.
Get Free Sample For